GKOS - Glaukos Corporation

NYSE - NYSE Delayed Price. Currency in USD
65.49
+1.00 (+1.55%)
At close: 4:02PM EDT

65.49 0.00 (0.00%)
After hours: 4:50PM EDT

Stock chart is not supported by your current browser
Previous Close64.49
Open64.80
Bid65.48 x 900
Ask65.49 x 900
Day's Range64.59 - 66.34
52 Week Range35.16 - 83.14
Volume183,907
Avg. Volume443,544
Market Cap2.384B
Beta (3Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateMay 4, 2017 - May 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est75.00
Trade prices are not sourced from all markets
  • Markit3 days ago

    See what the IHS Markit Score report has to say about Glaukos Corp.

    Glaukos Corp NYSE:GKOSView full report here! Summary * Bearish sentiment is low and declining Bearish sentimentShort interest | PositiveShort interest is low for GKOS with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 15. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold GKOS had net inflows of $729 million over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Glaukos (GKOS) Q1 2019 Earnings Call Transcript
    Motley Fool15 days ago

    Glaukos (GKOS) Q1 2019 Earnings Call Transcript

    GKOS earnings call for the period ending March 31, 2019.

  • Does This Valuation Of Glaukos Corporation (NYSE:GKOS) Imply Investors Are Overpaying?
    Simply Wall St.15 days ago

    Does This Valuation Of Glaukos Corporation (NYSE:GKOS) Imply Investors Are Overpaying?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Thomson Reuters StreetEvents16 days ago

    Edited Transcript of GKOS earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Glaukos Corp Earnings Call

  • Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
    Zacks16 days ago

    Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

    Glaukos (GKOS) delivered earnings and revenue surprises of 66.67% and 7.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press16 days ago

    Glaukos: 1Q Earnings Snapshot

    On a per-share basis, the San Clemente, California-based company said it had a loss of 4 cents. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...

  • Business Wire16 days ago

    Glaukos Corporation Announces First Quarter 2019 Financial Results

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the first quarter ended March 31, 2019.

  • ACCESSWIRE17 days ago

    Glaukos Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Glaukos Corp. (NYSE: GKOS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern Time. To ...

  • Business Wire23 days ago

    Multiple Surgeons to Present Data on Glaukos Technologies at 2019 American Society of Cataract and Refractive Surgery

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that numerous surgeons will present clinical trial and real-world data regarding it products at the American Society of Cataract and Refractory ...

  • Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for
    Zacks23 days ago

    Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for

    Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Did Hedge Funds Drop The Ball On Glaukos Corporation (GKOS)?
    Insider Monkey24 days ago

    Did Hedge Funds Drop The Ball On Glaukos Corporation (GKOS)?

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Business Wire24 days ago

    Glaukos Announces Participation in Bank of America Merrill Lynch 2019 Health Care Conference

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019, at 3:40 p.m. PDT in Las Vegas, Nevada.

  • Business Wire29 days ago

    Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States

    Santen Pharmaceutical Co., Ltd. (“Santen” TSE: 4536) and Glaukos Corporation (“Glaukos” NYSE: GKOS), announced today that Santen’s U.S. subsidiary, Santen Inc., has entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt (development code: DE-128) solely in the U.S. market. The MicroShunt is a novel, minimally-invasive, ab-externo surgical device being developed for primary open-angle glaucoma (POAG). Glaucoma is a leading cause of irreversible blindness, affecting several million people in the United States.

  • Business Wirelast month

    Glaukos Corporation to Release First Quarter 2019 Financial Results after Market Close on May 8

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release first quarter 2019 financial results after the market close on Wednesday, May 8, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 8, 2019.

  • Business Wirelast month

    Prospective, Randomized Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents® vs. Topical Prostaglandin in Newly Diagnosed Glaucoma Patients

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an international glaucoma study published in Ophthalmology Glaucoma showed standalone implantation of two iStent® Trabecular Micro-Bypass Stents in newly diagnosed primary open-angle glaucoma (POAG) eyes achieved a 35.3% reduction in mean intraocular pressure (IOP) to 16.5 mmHg after five years of follow-up.

  • Is Glaukos Corporation (NYSE:GKOS) A Volatile Stock?
    Simply Wall St.last month

    Is Glaukos Corporation (NYSE:GKOS) A Volatile Stock?

    If you own shares in Glaukos Corporation (NYSE:GKOS) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volat...

  • Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition
    Zacks2 months ago

    Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition

    Glaukos' (GKOS) strong pipeline is indicative of brighter prospects ahead. However, cutthroat competition in the medical-device industry is worrisome.

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for Fresh Del Monte Produce, Baker Hughes, a GE company, HollyFrontier, Glaukos, HCI Group, and Revance Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire2 months ago

    Pivotal Trial Results for Glaukos’ iStent inject® Published in Leading Ophthalmic Journal

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that the U.S. Investigational Device Exemption (IDE) pivotal trial results for its next-generation iStent inject® Trabecular Micro-Bypass System have been published in Ophthalmology. Results of the iStent inject prospective, randomized, controlled, multicenter clinical trial, which included 505 mild-to-moderate primary open-angle glaucoma (POAG) subjects from 41 investigational sites, formed the basis for Food & Drug Administration approval of the device in June 2018.

  • Business Wire2 months ago

    Glaukos Technologies Featured in Numerous Presentations at 2019 American Glaucoma Society Meeting

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be featured in various presentations at the American Glaucoma Society Annual Meeting on March 14-17, 2019 at the Marriott ...

  • When Should You Buy Glaukos Corporation (NYSE:GKOS)?
    Simply Wall St.2 months ago

    When Should You Buy Glaukos Corporation (NYSE:GKOS)?

    Glaukos Corporation (NYSE:GKOS), which is in the medical equipment business, and is based in United States, saw a significant share price rise of over 20% in the past couple ofRead More...

  • Business Wire2 months ago

    International Glaucoma Study Confirms Long-term Efficacy and Safety Profile of Glaukos iStent® Implantation in Combination with Cataract Surgery

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an international glaucoma study published in the Journal of Cataract and Refractive Surgery showed use of iStent® Trabecular Micro-Bypass Stent during cataract surgery delivered a 38% reduction in mean intraocular pressure (IOP) to 14.7 mmHg after five years of follow-up.

  • Why Glaukos Stock Jumped 16.3% in February
    Motley Fool3 months ago

    Why Glaukos Stock Jumped 16.3% in February

    Shares of this mid-cap ophthalmic medical tech and pharmaceutical company have soared 111% over the last year.